MIAMI, FL — September 16, 2025 — Immorta Bio Inc., a scientific longevity company dedicated to “Treating Diseases of Aging and Treating Aging as Disease™,” today announced the appointment of Gilberto de Lima Lopes Jr., MD, MBA, FAMS, to its Strategic Advisory Board.

Dr. Lopes is globally recognized for leadership in lung cancer and immuno-oncology. He was principal investigator of KEYNOTE-042, the trial that supported 2019 FDA first-line approval of pembrolizumab (Keytruda®) in PD-L1–positive advanced NSCLC broadening access to checkpoint inhibition for hundreds of thousands of patients worldwide since approval.

“We are honored to welcome a medical pioneer who helped bring game-changing immunotherapy to lung cancer,” said Boris N. Reznik, PhD,Chairman and CEO of Immorta Bio. “With Dr. Lopes’ guidance, we aim to deliver the next leap—senolytic immunotherapy—to patients who need new options.”

Immorta Bio’s lead program, SenoVax™, is a first-in-class senolytic immunotherapy designed to train the immune system to selectively eliminate senescent cells—aged, dysfunctional cells that accumulate in tumors and their microenvironment and are associated with immune evasion and resistance to therapy. In preclinical studies, SenoVax™ has demonstrated anti-tumor activity across multiple solid tumor models, including lung, breast, glioma, and pancreatic cancers, and synergy with checkpoint inhibitors. The company is working with the U.S. Food and DrugAdministration (FDA) to advance SenoVax™ into a Phase I/IIa study in advanced NSCLC.

“Our SenoVax™ program shows that removing senescent cells can de-shield tumors and enable immune-mediated destruction,” said Thomas E. Ichim, PhD, President and Chief Scientific Officer of Immorta Bio. “Beyond oncology, targeting senescence has the potential to restore youthful immune and regenerative function, a cornerstone of our longevity vision.”

“Joining Immorta Bio is an exciting opportunity to extend the promise of immunotherapy beyond traditional cancer care into longevity and healthy aging,” said Dr. Gilberto Lopes. “The concept behind SenoVax™—targeting senescent cells to enhance anti-tumor immunity—builds on the foundation established by checkpoint inhibitors like pembrolizumab. I look forward to helping guide the translation of this innovative science to patients.”

Keytruda® is a registered trademark of Merck & Co., Inc. Forward-looking statements apply

‍